At WVPA Congress, Edinburgh, the company outlines its latest innovations, in vaccines, equipment, services and quality certification.
At WVPA Congress, Edinburgh, the company outlines its latest innovations, in vaccines, equipment, services and quality certification.
At the World Veterinary Poultry Association Congress in Edinburgh, Ceva hosted a scientific symposium Mastering In Ovo Vaccination – A closer look at key details, focusing on the critical success factors for in ovo vaccination: embryo age and development, new solutions for improved chick quality and the essential steps to optimise in ovo vaccination.
With ever increasing demands on the poultry sector to produce in the most sustainable, safe and welfare minded way possible, further improvements of efficiency in the hatchery are critical to achieving these goals.
Ceva has invested significantly over the last decade developing the most complete portfolio of new technology vaccines products such as Transmune®, Vectormune® ND, In-ovo vaccination equipment with Egginject™ and now hatchery automation equipment with Laser Life™. Laser Life identifies all live eggs, vital in the in ovo process, as one dead or contaminated egg can spread contamination through injecting equipment causing severe disruption and waste.
In what Ceva believes is an important advance in in ovo vaccination, its latest Egginject™ adapts to every egg, as compared to older systems that inject to a uniform depth, which can result in poor or no vaccine uptake.
Ceva is also making excellent progress on the roll out of its C.H.I.C.K Programme, which earlier in the year became the first quality services program to be independently certified by Bureau Veritas. The programme has now been officially approved in South Africa, Spain, Turkey, The Philippines, Mexico, Russia, and Poland.
Innovation is the key to this new Vaccinology approach said, Dr. Sylvain Comte, Ceva’s Head of Poultry:
“After launching some of the most innovative vaccines that the poultry industry has seen in the last decade we realized vaccination alone is no longer enough. Ensuring that vaccines are applied correctly as part of a total preventative health programme is key to the future. We are delighted that internationally respected bodies such as Bureau Veritas have independently verified the quality of our service programmes but this is just the beginning, we now have to focus on how further we can use the huge amount of data we are collecting to help our customers continuously meet evolving consumer demands.”
About Ceva Santé Animale:
Ceva Santé Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne (Gironde).
Ceva Chairman and CEO is Marc Prikazsky.
Qvetech.com